000275423 001__ 275423
000275423 005__ 20240229154940.0
000275423 0247_ $$2doi$$a10.1097/HEP.0000000000000407
000275423 0247_ $$2pmid$$apmid:37055018
000275423 0247_ $$2ISSN$$a0270-9139
000275423 0247_ $$2ISSN$$a1527-3350
000275423 0247_ $$2altmetric$$aaltmetric:145743531
000275423 037__ $$aDKFZ-2023-00746
000275423 041__ $$aEnglish
000275423 082__ $$a610
000275423 1001_ $$0P:(DE-He78)95d56cbcb8b1bb5783526d136049e3df$$aDe Angelis Rigotti, Francesca$$b0$$eFirst author
000275423 245__ $$aSemaphorin 3C exacerbates liver fibrosis.
000275423 260__ $$aNew York [u.a.]$$bWiley Interscience$$c2023
000275423 3367_ $$2DRIVER$$aarticle
000275423 3367_ $$2DataCite$$aOutput Types/Journal article
000275423 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697800767_29654
000275423 3367_ $$2BibTeX$$aARTICLE
000275423 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275423 3367_ $$00$$2EndNote$$aJournal Article
000275423 500__ $$a#EA:A270#LA:A270# / 2023 Oct 1;78(4):1092-1105
000275423 520__ $$aChronic liver disease is a growing epidemic, leading to fibrosis and cirrhosis. TGF-β is the pivotal pro-fibrogenic cytokine which activates hepatic stellate cells (HSC), yet, other molecules can modulate TGF-β signaling during liver fibrosis. Expression of the axon guidance molecules Semaphorins (SEMAs), which signal through Plexins and Neuropilins (NRPs), have been associated with liver fibrosis in HBV-induced chronic hepatitis. This study aims at determining their function in the regulation of HSCs. We analyzed publicly available patient databases and liver biopsies. We employed transgenic mice, in which genes are deleted only in activated HSCs to perform ex vivo analysis and animal models. SEMA3C is the most enriched member of the Semaphorin family in liver samples from cirrhotic patients. Higher expression of SEMA3C in patients with NASH, alcoholic hepatitis or HBV-induced hepatitis discriminates those with a more pro-fibrotic transcriptomic profile. SEMA3C expression is also elevated in different mouse models of liver fibrosis and in isolated HSCs upon activation. In keeping with this, deletion of SEMA3C in activated HSCs reduces myofibroblast marker expression. Conversely, SEMA3C overexpression exacerbates TGF-β-mediated myofibroblast activation, as shown by increased SMAD2 phosphorylation and target gene expression. Among SEMA3C receptors, only NRP2 expression is maintained upon activation of isolated HSCs. Interestingly, lack of NRP2 in those cells reduces myofibroblast marker expression. Finally, deletion of either SEMA3C or NRP2, specifically in activated HSCs, reduces liver fibrosis in mice. SEMA3C is a novel marker for activated HSCs that plays a fundamental role in the acquisition of the myofibroblastic phenotype and liver fibrosis.
000275423 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000275423 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275423 7001_ $$0P:(DE-He78)b27922c32bcdf07ca4d5f13ecdcfd100$$aWiedmann, Lena$$b1$$udkfz
000275423 7001_ $$0P:(DE-He78)c82d29f0b0709897fbdf50c5aa907d94$$aHubert, Max Ole$$b2
000275423 7001_ $$0P:(DE-He78)db0b2f396de01b200ce18462ab29fdbc$$aVacca, Margherita$$b3
000275423 7001_ $$0P:(DE-HGF)0$$aHasan, Sana S$$b4
000275423 7001_ $$0P:(DE-He78)68d90eb013f51c689f9ebea83a920858$$aMoll, Iris$$b5$$udkfz
000275423 7001_ $$aCarvajal, Silvia$$b6
000275423 7001_ $$aJiménez, Wladimiro$$b7
000275423 7001_ $$0P:(DE-He78)ab745a01a81217d94e152f2c7a815a20$$aStarostecka, Maja$$b8
000275423 7001_ $$aBilleter, Adrian T$$b9
000275423 7001_ $$aMüller-Stich, Beat$$b10
000275423 7001_ $$aWolff, Gretchen$$b11
000275423 7001_ $$aEkim-Üstünel, Bilgen$$b12
000275423 7001_ $$aHerzig, Stephan$$b13
000275423 7001_ $$aFandos-Ramo, Cristina$$b14
000275423 7001_ $$aKrätzner, Ralph$$b15
000275423 7001_ $$aReich, Maria$$b16
000275423 7001_ $$aKeitel-Anselmino, Verena$$b17
000275423 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b18$$udkfz
000275423 7001_ $$aMogler, Carolin$$b19
000275423 7001_ $$aFischer, Andreas$$b20
000275423 7001_ $$0P:(DE-HGF)0$$aRodriguez-Vita, Juan$$b21$$eLast author
000275423 773__ $$0PERI:(DE-600)1472120-X$$a10.1097/HEP.0000000000000407$$gVol. Publish Ahead of Print$$n4$$p1092-1105$$tHepatology$$v78$$x0270-9139$$y2023
000275423 909CO $$ooai:inrepo02.dkfz.de:275423$$pVDB
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)95d56cbcb8b1bb5783526d136049e3df$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b27922c32bcdf07ca4d5f13ecdcfd100$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c82d29f0b0709897fbdf50c5aa907d94$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)db0b2f396de01b200ce18462ab29fdbc$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)68d90eb013f51c689f9ebea83a920858$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ab745a01a81217d94e152f2c7a815a20$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000275423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000275423 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000275423 9141_ $$y2023
000275423 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-19$$wger
000275423 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-19
000275423 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000275423 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000275423 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-22$$wger
000275423 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEPATOLOGY : 2022$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000275423 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bHEPATOLOGY : 2022$$d2023-08-22
000275423 9202_ $$0I:(DE-He78)A270-20160331$$kA270$$lA270 Vaskuläre Signaltransduktion und Krebs$$x0
000275423 9201_ $$0I:(DE-He78)A270-20160331$$kA270$$lA270 Vaskuläre Signaltransduktion und Krebs$$x0
000275423 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lF180 Chronische Entzündung und Krebs$$x1
000275423 9200_ $$0I:(DE-He78)A270-20160331$$kA270$$lA270 Vaskuläre Signaltransduktion und Krebs$$x0
000275423 980__ $$ajournal
000275423 980__ $$aVDB
000275423 980__ $$aI:(DE-He78)A270-20160331
000275423 980__ $$aI:(DE-He78)F180-20160331
000275423 980__ $$aUNRESTRICTED